Invitae Corp

Invitae Corporation is a medical genetics company that operates internationally. It provides genetic testing services to assist in family planning, inherited disease diagnosis, treatment and monitoring of cancer, and proactive health screening. Founded in 2010, Invitae Corporation has its headquarters in San Francisco, California. Formerly known as Locus Development, Inc., the company changed its name to Invitae Corporation in 2012. The company's tests aim to help healthcare providers identify disease patterns and improve outcomes by quickly and accurately identifying precise treatment paths. Invitae delivers its tests through a platform that serves biopharma companies, healthcare providers, patients, and other partners. The company applies bioinformatics software, robotics, process automation, and design solutions to improve efficiency in sample processing and interpretation. Invitae's genetic testing covers a variety of areas, including rare diseases, metabolic conditions, oncology, paediatrics, cardiology, neurology, and hereditary cancer. Stock for Invitae is listed on the NYSE under the ticker NVTA. The company has a collaboration agreement to develop a production-scale high-throughput HiFi sequencing platform with Pacific Biosciences of California, Inc. On 20th April, 2021, Invitae announced plans to open a new facility to provide laboratory and production services in North Carolina to meet the growing demand for genetic testing services. Track NVTA share price changes by adding it to your eToro virtual portfolio.